PureTech Health (NASDAQ:PRTC – Get Free Report) and Grace Therapeutics (NASDAQ:GRCE – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.
Profitability
This table compares PureTech Health and Grace Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PureTech Health | N/A | N/A | N/A |
| Grace Therapeutics | N/A | -15.58% | -14.51% |
Analyst Recommendations
This is a summary of current recommendations and price targets for PureTech Health and Grace Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PureTech Health | 1 | 0 | 0 | 0 | 1.00 |
| Grace Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Earnings and Valuation
This table compares PureTech Health and Grace Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PureTech Health | $4.66 million | 91.01 | -$109.74 million | N/A | N/A |
| Grace Therapeutics | N/A | N/A | -$9.57 million | ($0.40) | -5.55 |
Grace Therapeutics has lower revenue, but higher earnings than PureTech Health.
Volatility and Risk
PureTech Health has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.
Institutional & Insider Ownership
0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 11.1% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Grace Therapeutics beats PureTech Health on 6 of the 10 factors compared between the two stocks.
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
About Grace Therapeutics
Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
